LigaChem Biosciences Inc.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2006 and listed on KOSDAQ in 2013, LigaChem Biosciences is a medicinal chemistry-based developer specializing in ADCs (antibody-drug conjugates) and synthetic new drugs. Based on its proprietary ADC platform technology ConjuALL, it holds a pipeline including Caxmotabart Entudotin (LCB14, HER2-ADC), CS5001 (LCB71, ROR1-ADC), LCB73 (CD19-ADC), LCB84 (TROP2-ADC), and LCB97 (L1CAM-ADC), alongside synthetic drug programs such as gram-negative and gram-positive antibiotics, and a medical device/consumables supply business. It has licensed LCB14 to China's Fosun Pharma and Iksuda, CS5001 to China's CStone, LCB84 to Janssen, and LCB97 plus its ADC platform to Japan's Ono Pharmaceutical, securing disclosed contract value of roughly KRW 9.4 trillion in milestones across its new drug pipeline.
Products & technology
- Medical consumables and devicesSupply of treatment materials to two hospitals in the Seoul metropolitan area
Clinical trials
data.go.kr11 MFDS clinical trial authorisations · 2013–2023 (Phase 1 8 · Phase 2a 2 · Phase 2 1)
- Phase 2aLCB01-03712023-07-27
6 trial sites
- Phase 2aLCB01-03712021-08-04
8 trial sites
- Phase 1LCB01-03712020-10-26
2 trial sites
- Phase 1LCB01-03712020-05-06
2 trial sites
- Phase 1LCB01-03712016-07-26
1 trial site
- Phase 2LCB01-03712016-05-25
16 trial sites
- Phase 1LCB01-03712015-07-02
1 trial site
- Phase 1KR-334932015-05-11
1 trial site
- Phase 1LCB01-03712014-05-07
1 trial site
- Phase 1LCB01-03712014-01-10
1 trial site
- Phase 1LCB01-03712013-01-17
1 trial site
R&D and key agreements
Source: DART corporate disclosureCaxmotabart Entudotin(LCB14) · HER2-ADC, 유방암 · 임상 1상 및 로슈사 케사일라 대비 임상 3상 진행 중 · Licensed to Fosun Pharma (China) and Iksuda (rest of world excluding China/Korea)
CS5001(LCB71) · ROR1-ADC · 미국·호주·중국 임상 1상, 허가임상 개시 앞두고 있음 · Licensed to China's CStone
LCB73 · CD19-ADC · 미국·유럽 임상 1상 진행 중 · Conducted through Iksuda
LCB84 · TROP2-ADC · 임상 1상 공동 진행 중 · Licensed to Janssen in December 2023
LCB97 · L1CAM-ADC · Two licensing agreements with Japan's Ono Pharmaceutical covering LCB97 and the ADC platform
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition